Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Hutchmed China Ltd ADR
(NQ:
HCM
)
18.47
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Hutchmed China Ltd ADR
< Previous
1
2
3
4
5
6
7
8
Next >
HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees
May 10, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 16th and 17th, 2023
May 09, 2023
From
Virtual Investor Conferences
Via
GlobeNewswire
HUTCHMED Out Licenses Fruquintinib To Takeda Outside China
January 23, 2023
Via
Benzinga
HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer
April 17, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Consolidated Communications, CRISPR Therapeutics And Other Big Stocks Moving Higher On Thursday
April 13, 2023
U.S. stocks traded higher, with the Dow Jones gaining over 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Intended Retirement of Independent Non-executive Director
April 11, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
Why Levi Strauss Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 06, 2023
Gainers Liquid Media Group Ltd. (NASDAQ: YVR) jumped 88.1% to $0.2719.
Via
Benzinga
Lamb Weston, TH International, AMC Entertainment And Other Big Stocks Moving Higher On Thursday
April 06, 2023
U.S. stocks traded lower, with the Dow Jones falling around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 04, 2023
Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43.
Via
Benzinga
Why Is HUTCHMED Stock Trading Higher Today?
April 04, 2023
HUTCHMED (China) Limited (NASDAQ: HCM) shares are trading higher on Tuesday after the company initiated enrollment registration for its ongoing Phase 2 trial of HMPL-453 for intrahepatic...
Via
Benzinga
HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations
April 04, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
March 30, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China
March 14, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Confirms No Assets Held at Silicon Valley Bank
March 12, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Why Miromatrix Medical Shares Are Trading Lower By 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
March 08, 2023
Gainers Kimball International, Inc. (NASDAQ: KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million.
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
March 08, 2023
Via
Benzinga
HUTCHMED Reports 2022 Full Year Results and Provides Business Updates
February 28, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Completes Patient Enrollment of Phase II Registration Trial of Amdizalisib in Follicular Lymphoma in China
February 27, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Lyft, BARK And Other Big Stocks Moving Lower In Friday's Pre-Market Session
February 10, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
February 10, 2023
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development...
Via
Benzinga
HUTCHMED to Announce 2022 Final Results
January 31, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Dada Nexus, Bilibili And Other Big Stocks Moving Lower On Monday
January 30, 2023
U.S. stocks traded lower, with the Nasdaq Composite dropping over 100 points on Monday. Here are some big stocks recording losses in today’s session.
Via
Benzinga
Week In Review: HutchMed Announces $1.1 Billion Deal With Takeda For Colorectal Cancer Drug
January 28, 2023
Shanghai’s HutchMed out-licensed global rights for a colorectal cancer therapy to Japan’s Takeda in a deal worth up to $1.13 billion, including $400 million upfront. In addition to the $1.13 billion,...
Via
Talk Markets
HUTCHMED Announces License to Takeda to Develop and Commercialize Fruquintinib Outside China
January 23, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Announces Agreement with NHSA for Inclusion of ORPATHYS® in the National Reimbursement Drug List in China
January 18, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
Constellation Brands, Walgreens, RPM International And Some Other Big Stocks Moving Lower On Thursday
January 05, 2023
U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
HUTCHMED Completes Patient Enrollment of ESLIM-01, a Phase III Trial of Sovleplenib in Primary Immune Thrombocytopenia in China
January 03, 2023
From
HUTCHMED (China) Limited
Via
GlobeNewswire
HUTCHMED Initiates Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Colorectal Cancer
December 19, 2022
From
HUTCHMED (China) Limited
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.